Abstract
Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.
| Original language | English |
|---|---|
| Article number | 3038164 |
| Journal | PPAR Research |
| Volume | 2016 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology (medical)
Cite this
PPAR Gamma in Neuroblastoma : The Translational Perspectives of Hypoglycemic Drugs. / Vella, Serena; Conaldi, Pier Giulio; Florio, Tullio; Pagano, Aldo.
In: PPAR Research, Vol. 2016, 3038164, 2016.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - PPAR Gamma in Neuroblastoma
T2 - The Translational Perspectives of Hypoglycemic Drugs
AU - Vella, Serena
AU - Conaldi, Pier Giulio
AU - Florio, Tullio
AU - Pagano, Aldo
PY - 2016
Y1 - 2016
N2 - Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.
AB - Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.
UR - http://www.scopus.com/inward/record.url?scp=84992391012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992391012&partnerID=8YFLogxK
U2 - 10.1155/2016/3038164
DO - 10.1155/2016/3038164
M3 - Review article
VL - 2016
JO - PPAR Research
JF - PPAR Research
SN - 1687-4757
M1 - 3038164
ER -